Trichomonas vaginalis

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”

New Harris Poll Finds Women Want More Education on Sexually Transmitted Infections Testing and Treatment

Retrieved on: 
Wednesday, April 19, 2023
Medical Affairs Bureau, ACOG, Vaginitis, Education, Preventive healthcare, STI, Vagina, American College of Obstetricians and Gynecologists, Trichomonas vaginalis, Infection, Health, Bacterial vaginosis, Woman, Candidiasis, Neisseria gonorrhoeae, Approximation error, Centers for Disease Control and Prevention timeline, The Harris Poll, CDC, Becton, Dickinson and Company headquarters, Chlamydia trachomatis, Patient, Clutch (eggs), Becton, American College, BDX, NYSE, BD, Birth control, Diagnosis, Chlamydia, Trichomonas, Gynaecology

The survey of more than 1,000 U.S. women over 18 years old, found that while 77% of women say they are knowledgeable about vaginal infections (including yeast infections) in general, only 60% are knowledgeable about treatment options for vaginal infections and STIs.

Key Points: 
  • The survey of more than 1,000 U.S. women over 18 years old, found that while 77% of women say they are knowledgeable about vaginal infections (including yeast infections) in general, only 60% are knowledgeable about treatment options for vaginal infections and STIs.
  • The American College of Obstetricians and Gynecologists (ACOG) recommends that women be seen by their gynecologist at least once a year.
  • However, younger women (18-34 years old) are more likely than older women (45+ years old) to have visited an urgent care facility (26% vs. 5%).
  • *Results for Asian women are based on a small sample size (n

Visby Medical™ Receives FDA Clearance and CLIA Waiver for Second Generation Sexual Health Test for Women

Retrieved on: 
Tuesday, March 14, 2023
SAN, Pharmacy, Patient, Korea Disease Control and Prevention Agency, Food, Visby, STI, Associate, Neisseria gonorrhoeae, PCR, Gonorrhea, Trichomonas vaginalis, Risk, Prevention, Polymerase chain reaction, Woman, Workflow, Education, Health, Chlamydia trachomatis, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diagnosis, CLIA, POC, Stanford University, Pelvic inflammatory disease, Pharmaceutical industry, Birth control, Operation, Medicine, Neisseria, Trichomonas, Chlamydia

The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.

Key Points: 
  • The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.
  • The CLIA-waived, Sexual Health POC test provides accurate results in under 30 minutes, enabling clinicians to test, talk and accurately treat with confidence in a single patient visit.
  • "The Visby Sexual Health Test has been a game changer for us.
  • The Visby test is a win-win, helping fight antibiotic resistance as well as the spread of untreated infection, while empowering patients to engage health services with greater confidence."

Microbix Supporting Australian Point-of-Care Testing Program

Retrieved on: 
Wednesday, March 1, 2023
TSX, Test management, Gertrude Pocte Geddes Willis, Diagnosis, Neisseria gonorrhoeae, OTCQX, Chlamydia trachomatis, QAP (Colombia), Business development, STI, Trichomonas vaginalis, MDX, SVP, Health, Point-of-care testing, Medical device, Trichomonas, Chlamydia

MISSISSAUGA, Ontario, March 01, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products (“QAPs™”) are now supporting test accuracy within a program to provide Point-of-Care Testing (“PoCT”) for Sexually-Transmitted Infections (“STIs”) in remote communities across Australia.

Key Points: 
  • MISSISSAUGA, Ontario, March 01, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products (“QAPs™”) are now supporting test accuracy within a program to provide Point-of-Care Testing (“PoCT”) for Sexually-Transmitted Infections (“STIs”) in remote communities across Australia.
  • It is therefore honoured to be supporting this Australian program for STI testing in remote communities, which Microbix believes is providing a worldwide model for helping underserved populations.
  • Philip Hill, General Manager of r-Biopharm Australia commented, “r-Biopharm is pleased that the program will be delivering world-class diagnostic testing to some of the most remote populations in Australia.
  • This program, supported by PROCEEDxFLOQ QAPs, should help to provide the kind of testing needed in these Australian communities.”
    Microbix’s FLOQSwab-based QAPs support both STIs and other disease categories, with the full catalogue available at https://microbix.com and purchase enquiries directed to [email protected] .

Thermo Fisher Scientific Launches TrueMark STI Select Panel

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Alternative Energy, Environment, Energy, Science, STI, Thermo Fisher Scientific, Neisseria gonorrhoeae, Applied Biosystems, Korea Disease Control and Prevention Agency, Mycoplasma, PCR, MagMax, Genetic testing, Trichomonas vaginalis, Ribonuclease P, Chlamydia trachomatis, CDC, Syphilis, Genetic, Gonorrhea, Polymerase chain reaction, Mycoplasma genitalium, Vaccine, Neisseria, Chlamydia, Trichomonas

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.
  • The Applied Biosystems TrueMark STI Select Panel simultaneously tests for the four common STIs on the same panel, helping labs save time that would have been otherwise needed to run each on their own.
  • The TrueMark STI Select Panel is sold as a combo kit, which includes the STI panel assay and master mix; positive controls are also included for added accuracy and efficiency.
  • For more information on Thermo Fisher’s TrueMark STI Panel, please visit: https://www.thermofisher.com/truemarkstiselectpanel
    For Research Use Only.

BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

Retrieved on: 
Thursday, May 12, 2022
Risk, DNA, STI, Disease, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Urine, CT, BD, Patient, Solution, Health, Trichomonas, CE, COVID-19, Collection, Becton, FDA, Efficiency, GC, Female, Trichomonas vaginalis, Pregnancy, Neisseria gonorrhoeae, Safety, Organization, MX, BDX, Human papillomavirus infection, Therapy, LinkedIn, Twitter, HIV, Becton, Dickinson and Company headquarters, GX, Male, Laboratory, NYSE, Chlamydia trachomatis, HPV, Pharmaceutical industry, Medical device, Chlamydia

FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.

Key Points: 
  • FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.
  • With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new BD COR MX instrument is a new analytic instrument option for the BD COR System.
  • The BD COR MX/PX System integrates and automates the complete molecular laboratory workflow, from sample processing to diagnostic test result for large, high-throughput labs.
  • The BD COR System is fully automated, modular, and scalable instrument, designed to address multiple needs within laboratories to handle expanding molecular testing volumes.

Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise

Retrieved on: 
Wednesday, May 4, 2022
Aline (song), COVID-19, Pandemic, Population, HIV, Incidence, Twitter, STI, Neisseria gonorrhoeae, Mycoplasma genitalium, Sexually transmitted infection, Human services, NYSE, Nutritional challenges of HIV/AIDS, Time, HBV, CDC, PCR, Patient, Projected, HIV-1, Becker, Infection, Polymerase chain reaction, Syphilis, Geography, STD, CT, FDA, Chlamydia trachomatis, Hepatitis, HCV, American Journal of Preventive Medicine, Hepatitis B, Center, Journal, Workflow, The Journal of Infectious Diseases, Severe acute respiratory syndrome coronavirus 2, Efficiency, Korea Disease Control and Prevention Agency, Gonorrhea, United States Department of Health and Human Services, Trichomonas vaginalis, LinkedIn, NG, Life, Technology, Emergency Use Authorization, Cancer, Mycoplasma, Risk, Birth control, Pharmaceutical industry, Vaccine, Chlamydia, Trichomonas

The test simultaneously detects and differentiates four common sexually transmitted infections (STIs).

Key Points: 
  • The test simultaneously detects and differentiates four common sexually transmitted infections (STIs).
  • The test runs on Abbott's Alinity m system the company's most advanced high-volume laboratory molecular instrument.
  • This test can help healthcare providers save time, increase efficiency and better serve patients.
  • CDC estimates 1 in 5 people in the U.S. have a sexually transmitted infection, https://www.cdc.gov/media/releases/2021/p0125-sexualy-transmitted-infect...
    5.

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Retrieved on: 
Tuesday, April 19, 2022
Patent, Human papillomavirus infection, New York State Department of Health, Trichomonas, Achievement, LDT, Cervical cancer, Vertically transmitted infection, Mycoplasma, DOH, American Cancer Society, GLOBE, Risk, ENZ, Maritime Transportation Security Act of 2002, Infection, HPV, Securities Exchange Act of 1934, Intellectual property, Mycoplasmataceae, Review, BV, Company, Neisseria gonorrhoeae, Trichomonas vaginalis, Chlamydia trachomatis, NYSE, Candida, FDA, Securities Act of 1933, Health, Vaccine

NEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE HPV test.

Key Points: 
  • NEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE HPV test.
  • The AMPIPROBE HPV test is Enzos PCR-based test designed to detect 14 high-risk human papillomavirus (HPV) variants.
  • HPV testing is part of Enzos focus on womens health and oncology and leverages the Companys long history in HPV detection.
  • Almost all cervical cancers are linked to infection with high-risk HPV, an extremely common virus transmitted through sexual contact.

Point of Care Molecular Diagnostics Market by Product, Application, Technology, End-user and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 16, 2022
Science, Health, Other Science, Other Health, Product-service system, Degenerative disease, HIV, Subclinical infection, Assay, Prevalence, STD, HPV, Infection, Awareness, Intensive care unit, Trichomonas vaginalis, Vertically transmitted infection, Instrument, USD, Eyeish, Software, Physician, Growth, POC, CAGR, Medical imaging, Vaccine, Medical device, Technology, Hepatitis, Cancer, Hospital, Trichomonas

The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2% during the forecast period.

Key Points: 
  • The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2% during the forecast period.
  • The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period
    The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services.
  • The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2020.
  • The global point-of-care molecular diagnostics market is segmented into North America, Europe, Asia Pacific and the Rest of the World.

Rheonix Receives FDA Clearance for Fully Automated Encompass MDx® Workstation and Molecular Test for Detection of Sexually Transmitted Infections

Retrieved on: 
Monday, January 10, 2022
FDA, Health, Infectious Diseases, Research, Science, Biotechnology, Neisseria gonorrhoeae, Research, Male, RT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NGS, COVID-19, Virus, Inc., Severe acute respiratory syndrome coronavirus 2, Chlamydia trachomatis, EUA, CEO, STI, DNA, Automation, Degenerative disease, Urine, Beer, Diagnosis, Trichomonas vaginalis, Food, FDA, Encompass, Laboratory, Medical device, Pharmaceutical industry, Vaccine, Listeria, Trichomonas, Neisseria, Chlamydia, Rheonix, Emergency Use Authorization Status, RHEONIX, EMERGENCY USE AUTHORIZATION STATUS

The fully automated Encompass MDx workstation enables multiplexed sample-to-answer detection, simplifying laboratory workflows and significantly reducing the burden on laboratory technicians.

Key Points: 
  • The fully automated Encompass MDx workstation enables multiplexed sample-to-answer detection, simplifying laboratory workflows and significantly reducing the burden on laboratory technicians.
  • Since early in the coronavirus pandemic, the Rheonix Encompass MDx workstation has been used in combination with the Rheonix COVID-19 MDx Assay under FDA emergency use authorization (EUA) to enable same-day COVID-19 testing in local and regional laboratories.
  • Rheonix has developed the suite of Encompass workstations, fully automated systems that provide highly multiplexed sample-to-answer molecular testing for use in clinical, research and applied testing laboratories.
  • Rheonixs clinical assays include the Rheonix COVID-19 MDx Assay for use under FDA emergency use authorization, and the STI TriPlex Assay for the detection of sexually transmitted infections in male urine.